Unravel Biosciences

Unravel Biosciences is a private, preclinical-stage biotech founded in 2019 and based in Cambridge, Massachusetts. The company has developed a proprietary AI-driven platform that analyzes patient RNA signatures to create digital twin models, enabling the discovery of new therapeutic mechanisms and the repurposing of existing drugs. This approach aims to accelerate clinical validation and derisk development, as evidenced by its lead program for Rett syndrome which has received FDA Orphan Drug Designation and entered clinical testing. Unravel operates a hybrid business model, both discovering its own therapeutics and partnering its platform for drug discovery collaborations.

AI-driven platform that uses patient RNAseq data to build 'Living Molecular Twins' (digital twin biological network models) to identify dysregulated pathways and predict therapeutic interventions, enabling drug repurposing and novel target discovery.

Unravel competes in the crowded AI/ML drug discovery sector against companies like Recursion, Exscientia, and Insilico Medicine. Its differentiation lies in its patient-centric 'Living Molecular Twins,' focus on clinical derisking via repurposing, and rapid *in vivo* model generation. It also competes with traditional rare disease biotechs and drug repurposing specialists.